Cytokinetics Announces Positive Results from a Pivotal Phase 3 Clinical Trial of Aficamten
December 29, 2023
0
Cytokinetics We recently became enthusiastic about Cytokinetics’ (CYTK) current clinical trial results. A few days ago, Cytokinetics announced positive results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Why the Great Enthusiasm? The following has been behind our enthusiasm . . . This …